Collect

Blood in purple-top (EDTA) tube. Saliva is also acceptable.

 

Storage/Transport Temperature

Room Temperature

Performed

Monday-Friday 9:00am - 4:00pm

Volume Required

3-5 mL

Minimum Required

1.5 mL

Phlebotomy Draw

Yes

Performed

Monday-Friday 9:00am - 4:00pm

Reported

28 days

Synonyms

  • ATM, BRCA1, BRCA2, BRIP1, CBL, CEBPA, CHEK2, DDX41, ETV6, FAS, G6PC3, GATA2, HAX1, HFE, IKZF1, ITK, KRAS, MPL, NBN, NF1, PALB2, PAX5, PTPN11, RUNX1, SBDS, SH2B3, SH2D1A, STAT3, TERT, TP53, WAS
  • HLEUP
  • Leukemia, Lymphoma

LIS Mnemonic

HLEUP

Performed By

Division of Genomic Diagnostics

Available STAT

No

Reflex Testing

Analysis of comprehensive hereditary cancer panel

Test Notes

Targeted Capture followed by Massively Parallel Sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA), and/or Array CGH Analysis (aCGH).

Clinical Features

The CHOP Hereditary Leukemia/Lymphoma Panel utilizes next-generation sequencing technology to simultaneously analyze a panel of genes known to be associated with increased risk for leukemia and lymphoma. This test should be used when a patient's medical and family histories strongly suggest an underlying genetic etiology of cancer. Thirty-one genes known to be associated with leukemia and lymphoma predisposition are analyzed using Next Generation Sequence (NGS) technology. The genes included in this panel are ATM, BRCA1, BRCA2, BRIP1, CBL, CEBPA, CHEK2, DDX41, ETV6, FAS, G6PC3, GATA2, HAX1, HFE, IKZF1, ITK, KRAS, MPL, NBN, NF1, PALB2, PAX5, PTPN11, RUNX1, SBDS, SH2B3, SH2D1A, STAT3, TERT, TP53, and WAS. All coding exons of the 31 genes and 20 base pairs of 5' and 3' flanking intronic sequences are analyzed. All known intronic mutations of these genes are also evaluated. Pathogenic/likely pathogenic variants detected by NGS are confirmed by Sanger sequencing. The panel also evaluates gross copy number variations of these genes by analyzing NGS data, and by MLPA and/or aCGH when necessary. Certain genes or exons may not be evaluated for gross copy number variations, such as genes with no known gross deletion/duplication mutations, or genes or exons with pseudogenes or highly homologous sequences in the genome.

CPT Codes

81218, 81405, 81406, 81408, 81479 x20 81345, 81163, 81307
Collection

Collect

Blood in purple-top (EDTA) tube. Saliva is also acceptable.

 

Storage/Transport Temperature

Room Temperature

Performed

Monday-Friday 9:00am - 4:00pm

Volume Required

3-5 mL

Minimum Required

1.5 mL

Phlebotomy Draw

Yes
Ordering

Performed

Monday-Friday 9:00am - 4:00pm

Reported

28 days

Synonyms

  • ATM, BRCA1, BRCA2, BRIP1, CBL, CEBPA, CHEK2, DDX41, ETV6, FAS, G6PC3, GATA2, HAX1, HFE, IKZF1, ITK, KRAS, MPL, NBN, NF1, PALB2, PAX5, PTPN11, RUNX1, SBDS, SH2B3, SH2D1A, STAT3, TERT, TP53, WAS
  • HLEUP
  • Leukemia, Lymphoma

LIS Mnemonic

HLEUP

Performed By

Division of Genomic Diagnostics

Available STAT

No

Reflex Testing

Analysis of comprehensive hereditary cancer panel

Test Notes

Targeted Capture followed by Massively Parallel Sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA), and/or Array CGH Analysis (aCGH).

Clinical Features

The CHOP Hereditary Leukemia/Lymphoma Panel utilizes next-generation sequencing technology to simultaneously analyze a panel of genes known to be associated with increased risk for leukemia and lymphoma. This test should be used when a patient's medical and family histories strongly suggest an underlying genetic etiology of cancer. Thirty-one genes known to be associated with leukemia and lymphoma predisposition are analyzed using Next Generation Sequence (NGS) technology. The genes included in this panel are ATM, BRCA1, BRCA2, BRIP1, CBL, CEBPA, CHEK2, DDX41, ETV6, FAS, G6PC3, GATA2, HAX1, HFE, IKZF1, ITK, KRAS, MPL, NBN, NF1, PALB2, PAX5, PTPN11, RUNX1, SBDS, SH2B3, SH2D1A, STAT3, TERT, TP53, and WAS. All coding exons of the 31 genes and 20 base pairs of 5' and 3' flanking intronic sequences are analyzed. All known intronic mutations of these genes are also evaluated. Pathogenic/likely pathogenic variants detected by NGS are confirmed by Sanger sequencing. The panel also evaluates gross copy number variations of these genes by analyzing NGS data, and by MLPA and/or aCGH when necessary. Certain genes or exons may not be evaluated for gross copy number variations, such as genes with no known gross deletion/duplication mutations, or genes or exons with pseudogenes or highly homologous sequences in the genome.
Result Interpretation
Administrative

CPT Codes

81218, 81405, 81406, 81408, 81479 x20 81345, 81163, 81307